Generic Medicine Info
Indications and Dosage
Mobilisation of haematopoietic stem cells for autologous transplantation in patients with lymphoma or multiple myeloma
Adult: In combination with granulocyte colony-stimulating factor (G-CSF): ≤83 kg: 20 mg fixed dose or 0.24 mg/kg once daily; >83 kg: 0.24 mg/kg once daily. Doses are usually given for 2-4 consecutive days (up to 7 days if required) and administered approx 6-11 hours prior to apheresis. Initiate treatment after 4 doses of G-CSF. Max: 40 mg daily.
Renal Impairment
CrCl (mL/min) Dosage
0.16 mg/kg once daily. Max: 27 mg daily.
Special Precautions
Not intended for stem cell mobilisation and collection in patients with leukaemia. Renal impairment. Pregnancy and lactation.
Adverse Reactions
Significant: Thrombocytopenia, leukocytosis, orthostatic hypotension, hypersensitivity reactions (e.g. urticaria, periorbital swelling, dyspnoea, hypoxia), splenomegaly or splenic rupture, syncope, inj site reactions.
Gastrointestinal disorders: Diarrhoea, nausea, vomiting, abdominal pain/discomfort, dyspepsia, constipation, flatulence, dry mouth.
General disorders and administration site conditions: Fatigue, hyperhidrosis.
Musculoskeletal and connective tissue disorders: Arthralgia.
Nervous system disorders: Dizziness, headache.
Psychiatric disorders: Insomnia.
Skin and subcutaneous tissue disorders: Erythema.
Potentially Fatal: Serious hypersensitivity reactions (e.g. anaphylactic shock).
Patient Counseling Information
This drug may cause dizziness, fatigue, or vasovagal reactions (e.g. orthostatic hypotension, syncope), if affected, do not drive or operate machinery.
Monitoring Parameters
Obtain CBC with differential and platelet count prior to and during therapy. Monitor total WBC count, neutrophil, and platelet count regularly and during apheresis. Assess for signs and symptoms of splenic integrity (e.g. left upper abdominal pain and/or scapular or shoulder pain).
Mechanism of Action: Plerixafor, a CXCR4 chemokine-receptor antagonist, blocks the binding of the ligand, stromal cell-derived factor-1α (SDF-1α) to the CXC chemokine receptor 4 (CXCR4) on CD34+ cells, resulting in mobilisation of haematopoietic stem and progenitor cells into the blood.
Absorption: Rapidly absorbed. Time to peak plasma concentration: Approx 30-60 minutes.
Distribution: Primarily distributed to the extravascular fluid space. Volume of distribution: 0.3 L/kg. Plasma protein binding: Approx 58%.
Excretion: Mainly via urine (approx 70%, as unchanged drug). Terminal elimination half-life: Approx 3-5 hours.
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Plerixafor, CID=65015, (accessed on Jan. 22, 2020)

Store at 25°C.
Any unused portions should be disposed of in accordance with local requirements.
MIMS Class
Haematopoietic Agents
ATC Classification
L03AX16 - plerixafor ; Belongs to the class of other immunostimulants.
Anon. Plerixafor. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 02/03/2018.

Buckingham R (ed). Plerixafor. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 02/03/2018.

Joint Formulary Committee. Plerixafor. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. Accessed 02/03/2018.

McEvoy GK, Snow EK, Miller J et al (eds). Plerixafor. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). Accessed 02/03/2018.

Mozobil Solution (Sanofi-Aventis U.S. LLC). DailyMed. Source: U.S. National Library of Medicine. Accessed 02/03/2018.

Disclaimer: This information is independently developed by MIMS based on Plerixafor from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2023 MIMS. All rights reserved. Powered by
  • Mozobil
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in